Andere talen Kringle Pharma, Inc.

Aandelen

4884

JP3270790003

Vertraagde tijd Japan Exchange Andere beurzen 08:00:00 06-06-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
711 ^JPY	-1,93%		+6,76%	-5,45%

13/05	Kringle Pharma, Inc. Geeft niet-geconsolideerde winstverwachting voor het boekjaar eindigend op 30 september 2024	CI
09/02	Kringle Pharma, Inc. Geeft winstverwachting voor het boekjaar dat eindigt op 30 september 2024	CI

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

Kringle Pharma, Inc. Provides Non-Consolidated Earnings Guidance for the Fiscal Year Ending September 30, 2024	13/05
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	09/02
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2024	28/11
Kringle Pharma, Inc. Completes Its Pre-Ind (Investigation New Drug) Meeting with the U.S. Food and Drug Administration Regarding the Development Plan of Kp-100It, A Lyophilized Formulation of Recombinant Human Hgf, for the Potential Treatment of Acute Spinal Cord Injury	17/11
Kringle's Preclinical Research Shows Encouraging Results for Dual Therapy Approach in Treating Acute Spinal Cord Injuries	31-10-23
Kringle Pharma, Inc. Announces Publication of Preclinical Results from Joint Research with Keio University on Severe Spinal Cord Injury	30-10-23
Kringle Pharma, Inc. Announces Last Patient Out in Phase 3 Study of KP-100IT for the Treatment of Acute Spinal Cord Injury	02-10-23
Kringle Pharma, Inc. announced that it has received ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	04-09-23
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	30-08-23
Kringle Pharma, Inc. announced that it expects to receive ¥1.242 million in funding from Barclays Bank PLC (Tokyo Branch)	14-08-23
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	30-05-23
Kringle Pharma Completes Patient Enrollment for Acute Spinal Cord Injury Treatment	14-04-23
Kringle Pharma, Inc. Announces Last Patient Enrolled in Phase Iii Study for the Treatment of Acute Spinal Cord Injury	13-04-23
Kringle Pharma Files Patent Application for Spinal Cord Injury Treatment	14-03-23
Kringle Pharma, Inc. Announces Patent Application Claims Priority for the Treatment of Chronic Spinal Cord Injury	13-03-23
Kringle Pharma, Inc. Provides Earnings Guidance for the Fiscal Year Ending September 30, 2023	28-02-23
Bank of Japan's Dovish Policy Bolsters Japanese Shares; Shionogi Proceeds with Pediatric Trial of COVID-19 Vaccine	18-01-23
Kringle Pharma Enrolls Initial Candidate in Clinical Study for Vocal Impairment Treatment	18-01-23
Kringle Pharma, Inc. Announces First Patient Enrollment in Phase III Clinical Study for the Treatment of Vocal Fold Scar	17-01-23
Kringle Pharma, Inc. Provides Update on Progress of Phase 3 Clinical Trial in Patients with Acute Spinal Cord Injury	13-01-23

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen Kringle Pharma, Inc.

Aandelen

4884

JP3270790003

Andere talen

Filters